|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moya-Horno I, Viteri S, Karachaliou N and
Rosell R: Combination of immunotherapy with targeted therapies in
advanced non-small cell lung cancer (NSCLC). Ther Adv Med Oncol.
10:17588340177450122018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó
L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alexandrov LB, Nik-Zainal S, Wedge DC,
Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A,
Børresen-Dale AL, et al: Signatures of mutational processes in
human cancer. Nature. 500:415–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Puig de la Bellacasa R, Karachaliou N,
Estrada-Tejedor R, Teixidó J, Costa C and Borrell JI: ALK and ROS1
as a joint target for the treatment of lung cancer: A review.
Transl Lung Cancer Res. 2:72–86. 2013.PubMed/NCBI
|
|
8
|
Wen M, Wang X, Sun Y, Xia J, Fan L, Xing
H, Zhang Z and Li X: Detection of EML4-ALK fusion gene and features
associated with EGFR mutations in Chinese patients with
non-small-cell lung cancer. Onco Targets Ther. 9:1989–1995. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim KA, Zhao J, Andarmani S, Kakitani M,
Oshima T, Binnerts ME, Abo A, Tomizuka K and Funk WD: R-Spondin
proteins: A novel link to beta-catenin activation. Cell Cycle.
5:23–26. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kazanskaya O, Glinka A, del Barco
Barrantes I, Stannek P, Niehrs C and Wu W: R-Spondin2 is a secreted
activator of Wnt/beta-catenin signaling and is required for Xenopus
myogenesis. Dev Cell. 7:525–534. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
de Lau WB, Snel B and Clevers HC: The
R-spondin protein family. Genome Biol. 13:2422012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rong X, Chen C, Zhou P, Zhou Y, Li Y, Lu
L, Liu Y, Zhou J and Duan C: R-spondin 3 regulates dorsoventral and
anteroposterior patterning by antagonizing Wnt/β-catenin signaling
in zebrafish embryos. PLoS One. 9:e995142014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sher I, Yeh BK, Mohammadi M, Adir N and
Ron D: Structure-based mutational analyses in FGF7 identify new
residues involved in specific interaction with FGFR2IIIb. FEBS
Lett. 552:150–154. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zebisch M, Xu Y, Krastev C, MacDonald BT,
Chen M, Gilbert RJ, He X and Jones EY: Structural and molecular
basis of ZNRF3/RNF43 transmembrane ubiquitin ligase inhibition by
the Wnt agonist R-spondin. Nat Commun. 4:27872013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim KA, Wagle M, Tran K, Zhan X, Dixon MA,
Liu S, Gros D, Korver W, Yonkovich S, Tomasevic N, et al: R-Spondin
family members regulate the Wnt pathway by a common mechanism. Mol
Biol Cell. 19:2588–2596. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Planas-Paz L, Orsini V, Boulter L,
Calabrese D, Pikiolek M, Nigsch F, Xie Y, Roma G, Donovan A, Marti
P, et al: The RSPO-LGR4/5-ZNRF3/RNF43 module controls liver
zonation and size. Nat Cell Biol. 18:467–479. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kazanskaya O, Ohkawara B, Heroult M, Wu W,
Maltry N, Augustin HG and Niehrs C: The Wnt signaling regulator
R-spondin 3 promotes angioblast and vascular development.
Development. 135:3655–3664. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Seshagiri S, Stawiski EW, Durinck S,
Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, Guan Y, Janakiraman
V, Jaiswal BS, et al: Recurrent R-spondin fusions in colon cancer.
Nature. 488:660–664. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Han T, Schatoff EM, Murphy C, Zafra MP,
Wilkinson JE, Elemento O and Dow LE: R-spondin chromosome
rearrangements drive Wnt-dependent tumour initiation and
maintenance in the intestine. Nat Commun. 8:159452017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou X, Geng L, Wang D, Yi H, Talmon G and
Wang J: R-spondin1/LGR5 activates TGFβ signaling and suppresses
colon cancer metastasis. Cancer Res. 77:6589–6602. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Barretina J, Caponigro G, Stransky N,
Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV,
Sonkin D, et al: The cancer cell line encyclopedia enables
predictive modelling of anticancer drug sensitivity. Nature.
483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cancer facts and figures 2008American
Cancer Society; Atlanta, GA, USA: pp. 9–14. 2008
|
|
23
|
Hashimoto T, Ogawa R, Yoshida H, Taniguchi
H, Kojima M, Saito Y and Sekine S: EIF3E-RSPO2 and PIEZO1-RSPO2
fusions in colorectal traditional serrated adenoma. Histopathology.
75:266–273. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xing Y, Clements WK, Kimelman D and Xu W:
Crystal structure of a beta-catenin/axin complex suggests a
mechanism for the beta-catenin destruction complex. Genes Dev.
17:2753–2764. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Binnerts ME, Kim KA, Bright JM, Patel SM,
Tran K, Zhou M, Leung JM, Liu Y, Lomas WE III, Dixon M, et al:
R-Spondin1 regulates Wnt signaling by inhibiting internalization of
LRP6. Proc Natl Acad Sci USA. 104:14700–14705. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Szenker-Ravi E, Altunoglu U, Leushacke M,
Bosso-Lefèvre C, Khatoo M, Thi Tran H, Naert T, Noelanders R,
Hajamohideen A, Beneteau C, et al: RSPO2 inhibition of RNF43 and
ZNRF3 governs limb development independently of LGR4/5/6. Nature.
557:564–569. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Papapietro O, Teatero S, Thanabalasuriar
A, Yuki KE, Diez E, Zhu L, Kang E, Dhillon S, Muise AM, Durocher Y,
et al: R-spondin 2 signalling mediates susceptibility to fatal
infectious diarrhoea. Nat Commun. 4:18982013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ilmer M, Boiles AR, Regel I, Yokoi K,
Michalski CW, Wistuba II, Rodriguez J, Alt E and Vykoukal J: RSPO2
enhances canonical Wnt signaling to confer stemness-associated
traits to susceptible pancreatic cancer cells. Cancer Res.
75:1883–1896. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vidal V, Sacco S, Rocha AS, da Silva F,
Panzolini C, Dumontet T, Doan TM, Shan J, Rak-Raszewska A, Bird T,
et al: The adrenal capsule is a signaling center controlling cell
renewal and zonation through Rspo3. Genes Dev. 30:1389–1394. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Storm EE, Durinck S, de Sousa e Melo F,
Tremayne J, Kljavin N, Tan C, Ye X, Chiu C, Pham T, Hongo JA, et
al: Targeting PTPRK-RSPO3 colon tumours promotes differentiation
and loss of stem-cell function. Nature. 529:97–100. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hsu CK, Romano MT, Nanda A, Rashidghamat
E, Lee JYW, Huang HY, Songsantiphap C, Lee JY, Al-Ajmi H, Betz RC,
et al: Congenital anonychia and uncombable hair syndrome:
Coinheritance of homozygous mutations in RSPO4 and PADI3. J Invest
Dermatol. 137:1176–1179. 2017. View Article : Google Scholar : PubMed/NCBI
|
